Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence

Cancer Research

Volumn 66, Issue 9, 2006, Pages 4975-4982

  Anderson, Lesley A ^a   Johnston, Brian T ^b   Watson, R G Peter ^b   Murphy, Seamus J ^c   Ferguson, Heather R ^a   Comber, Harry ^d   McGuigan, Jim ^b   Reynolds, John V ^e   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS   (United Kingdom)

^c ULSTER HOSPITAL   (United Kingdom)

^d NATIONAL CANCER REGISTRY IRELAND   (Ireland)

^e ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CANCER STAGING; CHEMOPROPHYLAXIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TOLERANCE; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

ACETAMINOPHEN; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; HUMANS; MALE; METAPLASIA; MIDDLE AGED;

EID: 33646436171     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4253     Document Type: Article

References (55)

1. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33.
2. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
3. Murray L, Watson P, Johnston B, Sloan J, Mainie IM, Gavin A. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003;327:534-5.
4. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
5. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1996;92:212-5.
6. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993;54:402-7.
7. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
8. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992;1:265-9.
9. Moller H. Incidence of cancer of oesophagus, cardia, and stomach in Denmark. Eur J Cancer Prev 1992;1:159-64.
10. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26 Suppl 15:2-8.
11. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
12. Li M, Lotan R, Levin B, Tahara E, Lippman SM, Xu XC. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:545-9.
13. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-72.
14. Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an In vitro study. J Natl Cancer Inst 2002;94:422-9.
15. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.
16. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994;74:1847-54.
17. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:2326-33.
18. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001;12:88-93.
19. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23.
20. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9.
21. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000;11:376-81.
22. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:444-50.
23. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
24. Coogan PF, Rosenberg L, Palmer Jr, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9:119-23.
25. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-9.
26. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
27. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945-52.
28. Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:34-9.
29. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
30. Tsibouris P, Hendrickse MT, Isaacs PE. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther 2004;20:645-55.
31. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. Br J Cancer 1999;80 Suppl 1:95-103.
32. Harrington KE, Robson PJ, Kiely M, Livingstone MB, Lambe J, Gibney MJ. The North/South Ireland food consumption survey: survey design and methodology. Public Health Nutr 2001;4:1037-42.
33. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4.
34. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
35. Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: the Bristol Helicobacter project. Int J Epidemiol 2003;32:645-50.
36. McCarthy SN, Harrington KE, Kiely M, et al. Analyses of the anthropometric data from the North/South Ireland food consumption survey. Public Health Nutr 2001;4:1099-106.
37. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7.
38. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
39. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001;52:563-71.
40. Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2005;26:565-70.
41. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52.
42. O'Riordan JM, Tucker ON, Byrne PJ, et al. Factors influencing the development of Barrett's epithelium in the esophageal remnant postesophagectomy. Am J Gastroenterol 2004;99:205-11.
43. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002;21:6071-81.
44. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96.
45. Hamoui N, Peters JH, Schneider S, et al. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg 2004;139:712-6.
46. 2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells. Life Sci 2004;75:21-34.
47. Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 2005;26:1627-33.
48. Kuramochi H, Vallbohmer D, Uchida K, et al. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg 2004;8:1007-16.
49. Lagorce C, Paraf F, Vidaud D, et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003;42:457-65.
50. Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001;46:785-9.
51. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-7.
52. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
53. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
54. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
55. Jankowski J, Sharma P. Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther 2004;19 Suppl 1:54-9.